← Back to patent-cliff list

Dazdotuftide

Tier C — Watch / trade

Dazdotuftide

Tarsius Pharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type

Targets:NF-κB

Indications (approved):葡萄膜炎, 前葡萄膜炎, Glaucoma, 眼睛发炎

Regional status

US
Phase III
2021-09-20
EU
Phase III
2021-09-20
China
-
Japan
-

Synthetic routes & intermediates2 routes

Originator routes × 0Optimised (non-patent) × 2Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OptimisedRoute 1Steps 5 · Total yield /
(I)1062329-1-a—(II)1062329-1-a—(IIIb)1062329-1-a3978-80-1(IVa)1062329-1-a—(IVb)1062329-1-a—(V)1062329-1-a—(VIa)1062329-1-a29022-11-5(VIb)1062329-1-a4530-20-5(VII)1062329-1-a—(VIIIa)1062329-1-a154445-77-9(VIIIb)1062329-1-a200124-22-7(IX)1062329-1-a,(IX)1062329-1-b—API · Dazdotuftide
CodeCAS No.Intermediate
(I)1062329-1-a-4-Aminophenyl 2-(trimethylammonio)ethyl phosphate
(II)1062329-1-a-4-Diazoniophenyl 2-(trimethylazaniumyl)ethyl phosphate chloride
(IIIb)1062329-1-a3978-80-1(2S)-3-(4-Hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
(IVa)1062329-1-a-N-[[(9H-Fluoren-9-yl)methoxy]carbonyl]-3-[(E)-[4-([[2-(trimethylazaniumyl)ethoxy]phosphinato]oxy)phenyl]diazenyl]-L-tyrosine
(IVb)1062329-1-a-N-(tert-Butoxycarbonyl)-3-[(E)-[4-([[2-(trimethylazaniumyl)ethoxy]phosphinato]oxy)phenyl]diazenyl]-L-tyrosine
(V)1062329-1-a-Resin bound 3-[(E)-[4-([[2-(trimethylazaniumyl)ethoxy]phosphinato]oxy)phenyl]diazenyl]-L-tyrosine
(VIa)1062329-1-a29022-11-52-(9H-Fluoren-9-ylmethoxycarbonylamino)acetic acid
(VIb)1062329-1-a4530-20-5Available2-((tert-Butoxycarbonyl)amino)acetic acid
(VII)1062329-1-a-Resin bound glycyl-3-[(E)-[4-([[2-(trimethylazaniumyl)ethoxy]phosphinato]oxy)phenyl]diazenyl]-L-tyrosine
(VIIIa)1062329-1-a154445-77-9(2S)-2-{[(9H-Fluoren-9-ylmethoxy)carbonyl]amino}-5-[2-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]pentanoic acid
(VIIIb)1062329-1-a200124-22-7(2S)-2-{[(tert-Butoxy)carbonyl]amino}-5-{N'-[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)sulfonyl]carbamimidamido}pentanoic acid
(IX)1062329-1-a,(IX)1062329-1-b-Resin bound N5-[N-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidoyl]-L-ornithylglycyl-3-[(E)-[4-([[2-(trimethylazaniumyl)ethoxy]phosphinato]oxy)phenyl]diazenyl]-L-tyrosine
OptimisedRoute 2Steps 4 · Total yield /
(IX)1062329-1-a,(IX)1062329-1-b—(Xa)1062329-1-b71989-31-6(Xb)1062329-1-b15761-39-4(XI)1062329-1-b—(XIIa)1062329-1-b71989-26-9(XIIb)1062329-1-b2483-46-7(XIII)1062329-1-b—(XIVa)1062329-1-b71989-35-0(XIVb)1062329-1-b13734-40-2(XV)1062329-1-b—(XVI)1062329-1-b—API · Dazdotuftide
CodeCAS No.Intermediate
(IX)1062329-1-a,(IX)1062329-1-b-Resin bound N5-[N-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidoyl]-L-ornithylglycyl-3-[(E)-[4-([[2-(trimethylazaniumyl)ethoxy]phosphinato]oxy)phenyl]diazenyl]-L-tyrosine
(Xa)1062329-1-b71989-31-6(2S)-1-{[(9H-Fluoren-9-yl)methoxy]carbonyl}pyrrolidine-2-carboxylic acid
(Xb)1062329-1-b15761-39-4(2S)-1-[(2-Methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid
(XI)1062329-1-b-Resin bound [(2S)-3-(4-hydroxy-3-[(E)-[4-([[2-(trimethylazaniumyl)ethoxy]phosphinato]oxy)phenyl]diazenyl]phenyl)-2-([L-prolyl-N5-[N-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidoyl]-L-ornithylglycyl]amino)propanoyl]oxy
(XIIa)1062329-1-b71989-26-9(2S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid
(XIIb)1062329-1-b2483-46-7(2S)-2,6-Bis({[(tert-butoxy)carbonyl]amino})hexanoic acid
(XIII)1062329-1-b-Resin bound [(2S)-2-([N6-(tert-butoxycarbonyl)-L-lysyl-L-prolyl-N5-[N-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidoyl]-L-ornithylglycyl]amino)-3-(4-hydroxy-3-[(E)-[4-([[2-(trimethylazaniumyl)ethoxy]phosphinato]oxy)phenyl]diazenyl]phenyl)propanoyl]oxy
(XIVa)1062329-1-b71989-35-0O-tert-Butyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-threonine
(XIVb)1062329-1-b13734-40-2N-(tert-Butoxycarbonyl)-O-tert-butyl-L-threonine
(XV)1062329-1-b-Resin bound [(2S)-2-([O-tert-butyl-L-threonyl-N6-(tert-butoxycarbonyl)-L-lysyl-L-prolyl-N5-[N-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidoyl]-L-ornithylglycyl]amino)-3-(4-hydroxy-3-[(E)-[4-([[2-(trimethylazaniumyl)ethoxy]phosphinato]oxy)phenyl]diazenyl]phenyl)propanoyl]oxy
(XVI)1062329-1-b-L-Threonyl-L-lysyl-L-prolyl-L-arginylglycyl-3-[(E)-[4-([[2-(trimethylazaniumyl)ethoxy]phosphinato]oxy)phenyl]diazenyl]-L-tyrosine--trifluoroacetic acid (1/1)

Frequently asked questions

What are the approved indications of Dazdotuftide?

Approved indications include: 葡萄膜炎, 前葡萄膜炎, Glaucoma, 眼睛发炎.

When does the Dazdotuftide patent expire?

No public expiry year is available for Dazdotuftide yet; this page updates once verified.

How many synthesis routes are recorded for Dazdotuftide?

2 synthesis routes are recorded; the shortest is 4 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Dazdotuftide intermediates?

1 intermediate CAS of Dazdotuftide are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Dazdotuftide intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-21